Amgen Inc. vs International Business Machines Corporation: Strategic Comparison

This in-depth comparison examines Amgen Inc. and International Business Machines Corporation across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Amgen Inc. on its own, evaluating International Business Machines Corporation, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Amgen Inc. and International Business Machines Corporation is widest.

On the headline numbers, Amgen Inc. reports annual revenue of $36.8B against $67.5B for International Business Machines Corporation, while their respective market capitalizations stand at $228.2B and $216.3B. Both Amgen Inc. and International Business Machines Corporation are headquartered in United States, so they compete in a shared home market and regulatory environment.

Amgen Inc.: Amgen is one of the companies that created the biotechnology industry. Instead of synthesizing small-molecule drugs, it engineers living cells to make complex proteins, an approach it first commercialized with Epogen in 1989. Based in Thousand Oaks, California, it is best known for medicines in bone health, inflammation, cardiovascular disease and kidney disease, and since the 2023 Horizon acquisition in rare disease. Fiscal 2025 revenue was US$36.8 billion across a portfolio in which 14 products each sold more than US$1 billion, although several of the older brands are now losing both price and volume.

International Business Machines Corporation: IBM, nicknamed Big Blue, is one of the oldest technology companies still operating at scale. It missed the consumer internet and smartphone eras, sold its PC business to Lenovo in 2005, and spun off its managed infrastructure services unit as Kyndryl in 2021. What remains is a business-to-business company with four segments: Software, Consulting, Infrastructure, and Financing. In FY2025 it reported $67.5 billion in revenue and $10.6 billion in net income, with software the largest segment at about $30 billion. Its customers are mostly large banks, insurers, airlines, retailers, and governments that run critical systems on IBM Z mainframes and want help connecting those systems to public clouds and AI.

Amgen Inc. and International Business Machines Corporation pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Amgen Inc. and International Business Machines Corporation.

Amgen Inc. business model: Amgen operates a high-risk, high-reward biopharmaceutical business model. It spends heavily on research to discover and engineer new biologic drugs: US$7.3 billion in fiscal 2025, or 20.7% of product sales. Once a drug is approved by the FDA, Amgen secures a patent, granting them a temporary monopoly to sell the drug at a premium price. Because biologic drugs are grown from living cells rather than chemically synthesized, they are much harder for competitors to copy, resulting in slightly longer and more defensible monopolies than traditional pills.

International Business Machines Corporation business model: IBM makes money from four segments. Software ($29.96 billion in FY2025, about 44% of revenue) includes Red Hat Enterprise Linux and OpenShift, HashiCorp Terraform and Vault, Confluent data streaming (from March 2026), watsonx AI, automation, security, and mainframe transaction-processing software, sold mostly as subscriptions and recurring licenses. Consulting ($21.06 billion, about 31%) bills for strategy, technology implementation, and application management work, often deploying IBM and partner software. Infrastructure ($15.72 billion, about 23%) sells IBM Z mainframes, Power servers, storage, and related support; revenue rises sharply in the year after each new mainframe launch, such as the z17 in 2025. Financing ($0.74 billion) lends to clients buying IBM hardware and software.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Amgen Inc. stack up against those of International Business Machines Corporation.

Amgen Inc. competitive advantage: Amgen's main competitive advantage is experience making complex biologics at commercial scale, which it has done continuously since Epogen launched in 1989. Producing a glycosylated protein or a monoclonal antibody to a consistent specification requires validated facilities, process know-how and a regulatory record that take years to build, which is also why the company can turn the same capability toward biosimilars of competitor products. Its balance sheet lets it buy late-stage assets rather than rely only on internal discovery: Onyx, Otezla, Five Prime, ChemoCentryx and Horizon together cost about US$57 billion between 2013 and 2023.

International Business Machines Corporation competitive advantage: IBM's main advantage is how deeply it is built into the core systems of large regulated organizations. Banks, card networks, insurers, and governments run high-volume transaction processing on IBM Z, and moving those workloads is slow, risky, and expensive. On top of that installed base, Red Hat gives IBM a neutral hybrid cloud platform that runs on every major cloud, and IBM Consulting gives it a way to deliver software inside multi-year transformation projects. Few rivals combine mainframe hardware, open-source platform software, and a large consulting arm under one contract.

Future prospects matter as much as current results. The growth strategies below explain how Amgen Inc. and International Business Machines Corporation each plan to expand from here.

Amgen Inc. growth strategy: Amgen's growth plan has two parts: scale the newer medicines and buy what the pipeline does not supply. Recent launches and acquired products drove the 10% revenue growth in fiscal 2025, with Tezspire up 52% to US$1.48 billion, Repatha up 36% to US$3.02 billion, Evenity up 34% to US$2.10 billion, Uplizna up 73% to US$655 million and Imdelltra reaching US$627 million in its second year. The company is pushing into obesity with MariTide, now in six Phase 3 MARITIME studies, and runs a biosimilars business that produced about US$3.0 billion of fiscal 2025 sales across Pavblu, Mvasi, Amjevita and Wezlana.

International Business Machines Corporation growth strategy: IBM does not try to beat AWS, Microsoft Azure, or Google Cloud at selling public cloud capacity. It sells the software layer that runs across all of them and across on-premises data centers. Red Hat OpenShift and RHEL run applications anywhere, HashiCorp (acquired February 2025 for $6.4 billion) automates and secures multi-cloud infrastructure, and Confluent (acquired March 2026 for about $11 billion) streams real-time data into AI applications and agents. watsonx and the open-source Granite models target regulated companies that want AI with governance and data control. Consulting brings this software into client projects, and IBM reported a generative AI book of business above $12.5 billion since inception. Longer term, IBM is betting on quantum computing, with a roadmap toward a fault-tolerant system later this decade.

A closer look at the financial trajectory of Amgen Inc. and International Business Machines Corporation rounds out the comparison.

Amgen Inc.: Amgen is a cash-generative business with high product gross margins. In fiscal 2025 it reported US$36.8 billion of total revenues, US$7.7 billion of GAAP net income, a 25.8% GAAP operating margin, US$8.1 billion of free cash flow and US$5.1 billion of dividends paid. Its results used to depend on a few large franchises, first Epogen and Aranesp, then Enbrel. As those matured Amgen bought revenue instead: Onyx in 2013, Otezla in 2019 and Horizon Therapeutics for US$27.8 billion in 2023. That last deal is also the main reason for the balance sheet it now carries, with US$54.6 billion of debt outstanding at December 31, 2025, debt leverage of about 3.2 times EBITDA and US$2.8 billion of net interest expense in fiscal 2025.

International Business Machines Corporation: IBM's reported revenue fell from about $80 billion in 2016-2018 to $57.4 billion in 2021, mostly because the Kyndryl spin-off and earlier divestitures removed low-margin services. Since then the slimmer company has grown each year: $60.5 billion in 2022, $61.9 billion in 2023, $62.8 billion in 2024, and $67.5 billion in 2025 (up 7.6%). FY2025 net income from continuing operations was $10.6 billion and free cash flow was $14.7 billion. In Q2 2026, revenue rose 1% to $17.16 billion: software grew 5% to $7.76 billion, consulting was flat at $5.33 billion, and infrastructure fell 7% to $3.84 billion as IBM Z sales lapped the z17 launch. Some large software deals slipped out of the quarter, so IBM cut its 2026 constant-currency revenue growth forecast to 4-5% while keeping its target of about $1 billion more free cash flow than in 2025.